Beyond monoclonals: Multispecific antibodies
New biologic logic – Multispecific antibodies extend targeted therapy beyond one antigen or pathway. By combining binding sites, cell recruitment and defined valencies within one molecule, they enable mechanisms that conventional monoclonal antibodies or their combinations cannot reproduce with the same spatial and pharmacological control.
Multispecific antibodies recognize two or more antigens or epitopes and connect functions that would otherwise remain separate. Established examples are T-cell engagers that bind a disease-related antigen and CD3 expressed on T cells to induce MHC-independent cytotoxicity. Other concepts recruit NK cells or macrophages, combine checkpoint modulation with tumor targeting, or bring enzymes and substrates into proximity.
Other bi- and multispecifics act without immune-cell redirection. Dual-receptor antibodies can block compensatory signaling, while biparatopic antibodies bind two epitopes on the same target to increase avidity, promote clustering or accelerate internalization. Multispecificity can also improve tissue selectivity by requiring co-expression, antigen density or a defined spatial arrangement.
Format defines function
Today, more than 100 multispecific antibody formats are under clinical investigation. The field comprises IgG-like, fragment-based and hybrid architectures.
This diversity reflects a central principle: binding domains alone do not define activity. Geometry, valency, flexibility, affinity, half-life and Fc function jointly determine biological activity.
Fc-containing formats offer prolonged exposure and adjustable effector functions. Fc-free formats are smaller and may improve tissue penetration, but often require half-life extension. VHH, Fab and scFv modules allow additional specificities at defined positions. The optimal architecture depends on the intended mechanism rather than on a universal platform.
Beyond oncology
Clinical development of bi- and multispecifics has been led by oncology, particularly CD3-based T-cell engagers for hematological malignancies. The same engineering logic is expanding into solid tumors, inflammatory disease and autoimmunity.
Mechanisms include dual cytokine neutralization, selective depletion of pathogenic immune cells and simultaneous modulation of receptor pathways.
Engineering remains decisive
Greater functional control comes with increased molecular complexity. Chain pairing, expression, aggregation, stability, product heterogeneity and manufacturability must be considered early. Safety also depends on affinity, valency, target distribution and activation geometry. Conditional activation, Fc engineering and tuned binding kinetics can improve therapeutic windows.
Outlook
Multispecific antibodies represent a conceptual evolution from passive targeted blockade to active, programmable biologics. As computational design matures and safety-by-design engineering further refines toxicity profiles, these molecules have the potential to become a foundational backbone of targeted biological therapy. ν
Contact us:
Dr. Oliver Hill
Senior Director of Protein Engineering
YUMAB GmbH
Inhoffenstraße 7
38124 Braunschweig, Germany
info@yumab.com, +49 531 481170-0
This article is sponsored by YUMAB GmbH.
